Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich, Kristian, Christopher E M Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, et al. 2020. “Maintenance of Clinical Response and Consistent Safety Profile With up to 3 years of Continuous Treatment With Guselkumab: Results from the VOYAGE 1 and VOYAGE 2 Trials.”. Journal of the American Academy of Dermatology 82 (4): 936-45.